Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Jun 6:5:60.
doi: 10.1186/1471-2458-5-60.

Routine testing for IgG antibodies against hepatitis A virus in Israel

Affiliations

Routine testing for IgG antibodies against hepatitis A virus in Israel

Noah Samuels. BMC Public Health. .

Abstract

Background: Viral hepatitis is highly endemic in Israel, with the hepatitis A virus (HAV) responsible for most cases. Improved socioeconomic factors, as well as the universal vaccination of infants (introduced in 1999) has resulted in a decline in infection rates in Israel. This study examines the benefits of routine testing for anti-HAV IgG in high-risk population.

Methods: A retrospective examination of the files of teenage and adult patients (aged 16-99 years; mean 33.9) in two primary care clinics found 1,017 patients who had been tested for anti-HAV IgG antibodies for either general healthcare screening or ongoing follow-up for chronic illness. Seropositive patients were then asked regarding recall of past hepatitis (i.e. jaundice, regardless of viral etiology); post-exposure prophylaxis with immune serum immunoglobulin (ISG); and active immunization with inactivated virus. Seronegative patients were subsequently sent for active immunization.

Results: Of the 1,017 patient records studied (503 male, 514 female), a total of 692 were seropositive (354 males, 338 females; P = 0.113). Seropositivity rates increased with age (p < 0.005), and were highest among those born in Middle Eastern countries other than Israel (91.3%) and lowest among immigrants from South America (44.1%; P < 0.005). 456 of the seropositive patients were interviewed, of whom only 91 recalled past illness while 103 remembered receiving post-exposure prophylaxis (ISG) and 8 active vaccination. Those who were unaware of past infection were more likely to have been vaccinated with ISG than those who were aware (26.3% vs. 7.7%; p < 0.005).

Conclusion: The relatively high prevalence rate of anti-HAV seropositivity in our study may me due to the fact that the study was conducted in a primary care clinic or that it took place in Jerusalem, a relatively poor and densely populated Israeli city. Most of the seropostive patients had no recollection of prior infection, which can be explained by the fact that most hepatitis A infections occur during childhood and are asymptomatic. Routine testing for anti-HAV IgG in societies endemic for HAV would help prevent seropositive patients from receiving either post-exposure or preventive immunization and target seronegative patients for preventive vaccination.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Prevalence of positive HAV serology according to age (%)
Figure 2
Figure 2
Prevalence of positive HAV serology according to country of birth(%). * Eastern Bloc = former USSR and Eastern European countries** Western Bloc = North America and Western Europe

Similar articles

References

    1. Green MS, Block C, Slater P. Rise in the incidence of viral hepatitis in Israel despite improved socioeconomic conditions. Rev Infect Dis. 1989;11:464–69. - PubMed
    1. Anis E, Leventhal A, Roitman M, Slater PE. [Introduction of routine hepatitis A immunization in Israel: the first in the world. Hebrew] Harefuah. 2000;138:177–80. - PubMed
    1. Gdalevich M, Gillis D, Mimouni D, Grotto I, Shpilberg O. [Trends in epidemiology of hepatitis in the Israel Defense Forces – direction over several years. Hebrew] Harefuah. 2000;138:755–57. - PubMed
    1. Green MS, Aharonowitz G, Shohat T, Levine R, Anis E, Slater PE. The changing epidemiology of viral hepatitis A in Israel. Israel Med Assoc J. 2001;3:347–51. - PubMed
    1. Gdalevich M, Grotto I, Mandel Y, Mimouni D, Shemer J, Ashkenazi I. Hepatitis A antibody prevalence among young adults in Israel – the decline continues. Epidemiol Infect. 1988;121:477–79. doi: 10.1017/S0950268898001198. - DOI - PMC - PubMed

MeSH terms

Substances